Multibagger penny stock under Rs 30 jumps after announcement of Indian Patent Grant for Pflow, which was also featured on Shark Tank India
The stock is up by 17.6 per cent from its 52-week low of Rs 21.15 per share.
Dr. Ashish Rawandale Patil, Managing Director of Tejnaksh Healthcare Ltd, has achieved a significant milestone with the granting of an Indian patent for Pflow. This innovative, disposable, and portable home-based urine flow measurement test is designed to empower individuals to detect potential urinary issues early, from the comfort of their own homes. With this latest patent, Dr. Patil becomes the sole urologist in India to hold 11 patents, solidifying his position as a leading innovator in the field.
Pflow’s potential to revolutionize kidney healthcare in India was further highlighted by its appearance on Shark Tank India Season 2, Episode 15. This national recognition underscored the product’s ability to improve early diagnosis of urinary and kidney-related health concerns. As Pflow continues its journey, the company is excited to witness its positive impact on public health and the future of kidney care.
On Monday, shares of Tejnaksh Healthcare Ltd zoomed 5.83 per cent to Rs 24.87 per share with an intraday high of Rs 26 per share and an intraday low of Rs 24.70 per share from its previous closing of Rs 23.50 per share. The company's shares saw a spurt in volume by more than 6.28 times on BSE.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.
Tejnaksh Healthcare Ltd, established in 2008, is a prominent healthcare provider in India, primarily operating in Mumbai and Maharashtra. The company offers a comprehensive range of services, including multi-speciality and super-speciality hospitals, pathology labs, research and development, healthcare equipment, super-speciality training institutes, simulation institutes, stone analysis labs, education institutes, and pharmaceuticals. With a focus on urology, Tejnaksh Healthcare has made significant contributions to the field, boasting over 150 research papers, 23 innovations, and 13 patent applications. The company's revenue primarily stems from operations and surgeries, followed by pathology services, the sale of traded goods, and consultation fees.
According to the financials, Tejnaksh Healthcare (BSE Code: 539428) has a market cap of Rs 50.562 crore and its working capital requirements have reduced from 18.1 days to 10.7 days. The company reported positive numbers in its Quarterly Results (Q2FY25) and half-yearly results (H1FY25). The stock is up by 17.6 per cent from its 52-week low of Rs 21.15 per share.
Disclaimer: The article is for informational purposes only and not investment advice.